GB1275 Monotherapy and in Combination With an Anti-PD1 Antibody in Patients With Specified Advanced Solid Tumors or in Combination With Standard of Care in Patients With Metastatic Pancreatic Adenocarcinoma
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- 202
Summary
- Conditions
- Esophageal Adenocarcinoma
- Castration Resistant Prostate Cancer
- Esophageal Squamous Cell Carcinoma
- Triple -Negative Breast Cancer
- Gastric Adenocarcinoma
- Small Cell Lung Cancer
- Urothelial Carcinoma
- Gastroesophageal Junction Adenocarcinoma
- Head and Neck Squamous Cell Carcinoma
- Hepatocellular Carcinoma
- Microsatellite Stable Colorectal Cancer
- Non -Small Cell Lung Cancer
- Pancreatic Adenocarcinoma
- Renal Cell Carcinoma
- Type
- Interventional
- Phase
- Phase 1Phase 2
- Design
- Allocation: Non-RandomizedIntervention Model: Sequential AssignmentIntervention Model Description: Phase 1 - Dose Escalation of 3 different Regimen and Expansion Phase 2 - Basket of 3 CohortsMasking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 125 years
- Gender
- Both males and females
Description
Not Provided
Not Provided
Tracking Information
- NCT #
- NCT04060342
- Collaborators
- Merck Sharp & Dohme Corp.
- Investigators
- Not Provided
Get Well Soon